Roche and Ionis report Phase 3 sefaxersen cut proteinuria in IgA nephropathy

what happened

According to TradingView, Genentech, part of the Roche Group, and its partner Ionis Pharmaceuticals said that in the Phase 3 IMAgINATION study, sefaxersen achieved a statistically significant 43.1% reduction in proteinuria versus placebo at 37 weeks. The effect was measured by the 24-hour urine protein-to-creatinine ratio. Results were presented at ASN Kidney Week 2026, and more patients with baseline hematuria achieved its resolution on the drug.

The companies plan to share the data with health authorities. The drug is a once-monthly subcutaneous injection designed for self-administration. The study continues in blinded mode, with kidney function measured by eGFR at week 105.

why it matters

For Roche and Ionis this is an important clinical signal: a successful Phase 3 readout raises the chances of regulatory approval, though risks remain until regulators decide. For biotech equities the news is material, but it has no direct bearing on oil, currencies or interest rates.

market impact

Roche, Ionis: positive Phase 3 data supports expectations for the new kidney drug

tags

instruments